General Information of Drug (ID: DM8YGOI)

Drug Name
Quinolinic Acid Drug Info
Synonyms
quinolinic acid; Pyridine-2,3-dicarboxylic acid; 2,3-pyridinedicarboxylic acid; 89-00-9; quinolinate; Pyridine-2,3-dicarboxylate; 339155-13-4; UNII-F6F0HK1URN; AI3-63017; 2,3-PyridinedicarboxylicAcid; EINECS 201-874-8; pyridine-2,3-carboxylate; NSC 13127; F6F0HK1URN; CHEMBL286204; 2,3-pyridine dicarboxylic acid; CHEBI:16675; GJAWHXHKYYXBSV-UHFFFAOYSA-N; 2,3-Pyridinedicarboxylic acid, 99%; Pyridin-2,3-dicarbonsaeure; 2,3-pyridinedicarboxylate; SMR000112287; 2,3-pyridindicarbons; SR-01000075472; HSDB 7511; PubChem8035
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1066
ChEBI ID
CHEMBL286204
CAS Number
CAS 89-00-9
TTD Drug ID
DM8YGOI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Namn DM1EZ3N Discovery agent N.A. Investigative [1]
5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate DMGK05W Discovery agent N.A. Investigative [1]
Phthalic Acid DMF9T64 Discovery agent N.A. Investigative [1]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [3]
Methotrexate DM2TEOL Anterior urethra cancer Approved [4]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [5]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [5]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [6]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [7]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [8]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [9]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [5]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC) TTH29K0 NADC_MYCTU Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Fibroblast growth factor 1 (FGF1) OT8I64X8 FGF1_HUMAN Protein Interaction/Cellular Processes [2]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol. 2005 Sep;25(6):981-93. doi: 10.1007/s10571-005-8469-y.
3 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
4 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
5 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
6 Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
7 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
8 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
9 WNT7A/-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015 Jun;34(26):3452-62. doi: 10.1038/onc.2014.277. Epub 2014 Sep 1.
10 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.